Form 8-K · Current report
News Corp 8-K, filed Jul 23, 2026
- Filed
- CIK
- 0001564708
- Accession no.
- 0001564708-26-000158
Summary
News Corp disclosed to the Australian Securities Exchange that it repurchased 66,163 shares of its Class A common stock for about US$1.82 million on 22 July 2026 under its 2025 Repurchase Program, which authorizes up to US$1 billion of Class A and Class B common stock. The company said roughly US$380.5 million of that authorization has been used to date.
Key points
- The 22 July 2026 repurchases totaled 66,163 Class A common shares for US$1,816,458.85, at prices between US$27.295 and US$27.79.
- Cumulative repurchases reported as of the prior day were 9,697,532 shares for US$245,634,450.04, with about US$380,451,157 of the US$1 billion authorization used to date.
- Goldman Sachs & Co. LLC is named as the broker for the buy-back, which the company says is intended to enhance shareholder value.
- The 2025 Repurchase Program was authorized as of July 15, 2025 and covers Nasdaq-listed Class A and Class B common stock, not ASX-listed CDIs.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 8.01Other Events
- 9.01Financial Statements and Exhibits
From the filing
Item 8.01 Other Events. As previously reported, under News Corporation's (the "Company's") stock repurchase program (the "Repurchase Program"), the Company is authorized to acquire from time to time up to $1 billion in the aggregate of the Company's outstanding shares of Class A common stock and Class B common stock. Under the rules of the Australian Securities Exchange (the "ASX"), the Company is required to provide to the ASX, on a daily basis, disclosure of transactions pursuant to the Repurchase Program, if any. The Company also discloses information concerning the Repurchase Program in the Company's quarterly and annual reports. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.